Pfizer Inc. said that results from a midstage, six-week study of its drug that prevents the body from metabolizing fructose, a natural sugar found in fruits and vegetables, showed a statistically significant improvement in liver fat.
The medication, an inhibitor of the fructokinase enzyme, could reverse or prevent the progression of the liver disease nonalcoholic steatohepatitis, known as NASH, and perhaps even treat diabetes, according to the company.
“We were pleasantly surprised by the results,” said Pfizer Senior Vice President Morris Birnbaum, who leads the New York company’s internal medicine research division. “Beyond improving liver fat, we think we’re working with a mechanism that can be used more broadly to treat metabolic abnormalities.”